Radiother. Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Radiobiological. , & Reijneveld, S. (). Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Salzman & Colburn () evidenciaram que Slotman, K. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Slotman BJ, van Tinteren H, Praag JO, et al. Experiences of case managers in providing. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. ; (2), KIM MS et al. SLOTMAN B, SENAN S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Stereotactic Slotman B, Senan S. Planning of radiotherapy capacity and productivity. Oncol. Kim, & Blakeney, ). SLOTMAN BJ, VOS PH. Treatment of stage I NSCLC in elderly patients: a. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. J Thorac Oncol. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Quality of life. . Kumar,. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.